The tumor necrosis factor receptor-associated factors (TRAFs) comprise signal transducers of Toll-like receptor interleukin-1 family members, which trigger signaling transduction in innate immune responses. Tumor necrosis factor receptor-associated factor 6, a member of the TRAF family, has an E3 ubiquitin ligase activity that mediates lysine-63 (K63)-dependent ubiquitination. In recent years, TRAF6 has been suggested as an oncogene in various human cancer types. It was upregulated in several solid malignancies, such as pancreatic cancer, 1 colon cancer, 2 and gastric cancer, 3 and the overexpression of TRAF6 predicts a poor prognosis in patients with glioma and gastric cancer. 3, 4 Some evidence has shown that TRAF6 autoubiquitination-induced nuclear factor-κB (NF-κB) activation might promote tumor growth. However, we previously reported that TRAF6 does not affect NF-κB signaling in cancer cells under normal growth conditions. 5 Therefore, the mechanism by which TRAF6 contributes to cancer development and progression is not clear.
| INTRODUC TI ON
The tumor necrosis factor receptor-associated factors (TRAFs) comprise signal transducers of Toll-like receptor interleukin-1 family members, which trigger signaling transduction in innate immune responses. Tumor necrosis factor receptor-associated factor 6, a member of the TRAF family, has an E3 ubiquitin ligase activity that mediates lysine-63 (K63)-dependent ubiquitination. In recent years, TRAF6 has been suggested as an oncogene in various human cancer types. It was upregulated in several solid malignancies, such as pancreatic cancer, 1 colon cancer, 2 and gastric cancer, 3 and the overexpression of TRAF6 predicts a poor prognosis in patients with glioma and gastric cancer. 3, 4 Some evidence has shown that TRAF6
autoubiquitination-induced nuclear factor-κB (NF-κB) activation might promote tumor growth. However, we previously reported that TRAF6 does not affect NF-κB signaling in cancer cells under normal growth conditions. 5 Therefore, the mechanism by which TRAF6 contributes to cancer development and progression is not clear.
In the present study, we found that the high expression of TRAF6
is associated with malignant behavior of human cancers, such as increased cell proliferation and migration and poor differentiation in both oral cancer and breast cancer. Tumor necrosis factor receptorassociated factor 6 induces AKT ubiquitination and activation, which, in turn, contributes to the proliferation and migration of cancer cells.
Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been found to be involved in carcinogenesis in multiple cancers. However, the precise role of TRAF6 in cancer has not been extensively investigated and remains largely unknown. In this study, we aimed to investigate the biological function of TRAF6 and its underlying molecular mechanisms in cancer. A positive correlation between poor tumor differentiation and TRAF6 expression status was observed in both oral cancer and breast cancer. Overexpression of TRAF6 promoted proliferation, migration, and G 0 /G 1 to S phase transition in tumor cells. Tumor necrosis factor receptor-associated factor 6-mediated AKT ubiquitination and subsequent phosphorylation played an essential role in the control of tumor cell malignant behavior. In vivo treatment with TRAF6, but not the E3 ligase deficient TRAF6 mutant, facilitated tumor growth. Our findings indicate that TRAF6 contributes to malignant behavior of human cancers through promoting AKT ubiquitination and phosphorylation. Therefore, TRAF6 could serve as a therapeutic target in cancers.
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Taken together, these data suggest a crucial role of TRAF6-mediated AKT ubiquitination and phosphorylation in cancer progression.
| MATERIAL S AND ME THODS

| Patient specimens and immunohistochemical staining
Primary oral cancer tissues were collected from 53 patients who underwent surgical resection in the Department of Oral and
Maxillofacial Surgery (Ninth People's Hospital, Shanghai, China).
Among 53 cases, 40 patients had well and moderate differentiation by histology, whereas 13 patients had poor differentiation. Primary breast cancer tissue samples were collected from 54 patients at the Fudan University Shanghai Cancer Center (Shanghai, China). Of these 54 patients, 43 had well and moderate differentiation, whereas 11 patients had poor differentiation. Slides of the tissue sections (4 μm)
were incubated with primary Abs, washed, and reincubated with appropriate secondary Abs, adopting the method described previously. 6 The staining results were measured semiquantitatively using a computerized image analysis system as previously described. 
| Antibodies and reagents
The primary Abs used included: anti-TRAF6 Ab (Abcam), anti-TRAF2 
| Cell culture
The human tongue squamous carcinoma cell lines SCC9 and HN12
were obtained from Professor Li Mao, University of Maryland Dental School (Baltimore, MD, USA), as described previously. 8 The human breast cancer cell lines MCF-7 and MDA-MB-231 were purchased from ATCC (Manassas, VA, USA). The means of short tandem repeat profiling was used to test authenticity. The cells were cultured in high glucose DMEM or DMEM/Ham's F-12 (both from Gibco, Waltham, MA, USA) with 10% FBS (Gibco), penicillin (100 U/mL), and streptomycin (100 μg/mL) and were maintained at 37°C in 5% CO 2 .
| Real-time quantitative PCR analysis
Total RNA from 4 cell lines was extracted using TRIzol reagent 
| Immunoblotting analysis
For immunoblotting experiments, total protein (30 μg) was separated on 10% SDS-PAGE gels and transferred to PVDF membranes (Merck Millipore, Bedford, MA, USA). The levels of protein expression were evaluated by western blot as previously described in detail. 
| Methylation analysis
Bisulfite sequencing was used to analysis the methylation of TRAF6 promoter region. The EZ DNA Methylation Kit (Zymo, Orange, CA, USA) was used to undertake bisulfite conversion, and the NEB PCR cloning kit (New England Biolabs, Ipswich, MA,USA), was used to clone PCR products and sequence individual clones. 10 The primer sequences of bisulfite sequencing were: forward, 5′-TGTTATAAAAGYGTAGTTTGGGATT-3′;
and reverse, 5′-AATTCRAAAAAAATACCCCCTAAC-3′.
| Plasmid transfection
The expression plasmids for WT TRAF6 and TRAF2 were purchased from Genechem (Zhangjiang, Shanghai, China), and an E3 ligase-deficient TRAF6 C70A mutant plasmid was produced as previously described. 5 Every clone used in this study was verified by sequencing. were selected using a culture medium with G418 sulfate (Sigma) at a density of 600 μg/mL.
| RNA interference mediated gene silencing
The preparation of shRNA was undertaken using the pSuper.puro siRNA expression plasmid (Oligoengine, Seattle, WA, USA), as described previously. 11 The RNAi target sequence of TRAF6 was 5′-CCACGAAGAGAUAAUGGAU-3′. The shRNA constructs were then transfected with Lipofectamine into indicated cells. The transfected cells were selected with 1 μg/mL puromycin for 2 weeks.
| Cell proliferation assay
All the cells were seeded in 96-well plates at a density of 1 × 10 
| Colony formation assay
All the cells were seeded in 6-well plates at a density of 500 cells/ well. After 14 days of incubation, the colonies were washed with PBS, fixed with 4% paraformaldehyde for 30 minutes, stained with 0.1% crystal violet, and counted.
| Cell migration assay
This assay used 24-well plates with 8-μm-pore chambers (Millipore, Bedford, MA, USA). All the cells (3 × 10 4 ) were resuspended and then seeded in the upper chamber with 300 μL serumfree medium, while the lower chamber contained 600 μL medium with 10% FBS. After 24 hours of incubation at 37°C, the cells were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and counted under a microscope at 100× magnification. 
| Flow cytometry analysis of the cell cycle
The cells were cultured in serum-free medium for 24 hours and then cultured in medium with 10% FBS for 24 hours. TA B L E 1 Tumor necrosis factor receptor-associated factor 6 (TRAF6) expression in specimens of oral cancer and breast cancer according to patient and tumor characteristics cells were collected and fixed with precooling 75% ethanol at 4°C.
The following day, the 75% ethanol was removed, and the cells were incubated in propidium iodide solution (100 μg/mL) at room temperature for 20 minutes in the dark. The cell cycle experiment was analyzed by flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA).
| Ubiquitination assay
To avoid degradation by proteasomes in the ubiquitination detection experiments, all the cells were treated with a proteasome inhibitor (5 μmol/L) as described previously. 14 were killed with 5% carbon monoxide, and the tumors were excised and then fixed with 10% formalin for 24 hours for further analysis.
| Statistical analysis
All statistical calculations were carried out using SPSS 19.0 statistical software (SPSS, Abbott Laboratories, Chicago, IL, USA). Unpaired t tests were used for continuous normally distributed data expressed as the means ± SD between 2 unpaired groups, and a 1-way ANOVA test was adopted for multiple comparisons in multiple groups. The showed significantly stronger TRAF6 expression than those moderately (pG2) or well differentiated (pG1). There was no significant correlation between TRAF6 expression status and other patient characteristics.
We also present a survival analysis of TRAF6 using datasets from The Cancer Genome Atlas. It was found that high expression of TRAF6 is associated with poor recurrence-free survival in patients with head and neck cancer and poor overall survival in patients with breast cancer (Figure S1A,B) . By contrast, other TRAFs (eg, TRAF2)
show no association with prognosis ( Figure S1C ,D).
| Overexpression of TRAF6 promotes cancer cell proliferation, migration, and G 0 /G 1 to S phase transition
To investigate the potential effect of TRAF6 on the pathogenesis of cancers, we measured the levels of TRAF6 in two oral cancer cell 
| Overexpression of TRAF6 induces AKT ubiquitination and activation
Given that TRAF6 could function as an E3 ubiquitin ligase as well Figure 5A ). Also, TRAF6 mut was unable to promote cancer cell proliferation, colony formation, or F I G U R E 5 E3 ligase activity-dependent tumor necrosis factor receptor-associated factor 6 (TRAF6)-mediated AKT ubiquitination/ phosphorylation is crucial for its oncogenic function. A, E3 ligase-deficient TRAF6 mutant (mut) showed no effect on AKT ubiquitination/ phosphorylation and has no influence on nuclear factor-κB (NF-κB) or MAPK signaling. B-E, TRAF6 mut was unable to promote cancer cell proliferation (B), colony formation (C), or migration (D) and showed no influence on the cell cycle (E). NS, not statistically significant migration and showed no influence on the cell cycle ( Figure 5B-E 
| Overexpression of TRAF6 contributes to cancer cell proliferation in vivo
We next investigated whether TRAF6-mediated AKT activation pro- 
| D ISCUSS I ON
Recent studies indicate that TRAF6 is involved in cancer development. 1, 20, 21 It has also been reported that the amplification of the TRAF6 locus is a somatic and frequent event in several human cancer types. 2, 22 Research findings showed that TRAF6 is important in the activation of the protein kinase complex IKK, which directly activates NF-κB and, in turn, inhibits apoptosis. 23, 24 Therefore, TRAF6 is thought to function as a tumor activator by influencing apoptosis in cancer cells. However, our previous study showed that TRAF6 does not simply affect NF-κB signaling and apoptosis in cancer cells under . E, Cells following indicated treatments as described in (A) were subjected to flow cytometry analysis. Data represent mean ± SD, n = 3. **P < .01, Student's t test. NS, not statistically significant normal growth conditions. 5 Thus, the precise role of TRAF6 in cancer has not been extensively investigated.
In this report, we showed that TRAF6 is upregulated in highly malignant tumor cells, and its expression is correlated with poor tumor differentiation in both oral cancer and breast cancer. In addition, TRAF6 has an important role in AKT signaling activation through promoting its ubiquitination, and facilitates cell proliferation, colony formation, migration, and G 0 /G 1 to S phase transition in cancer cells. Our data also showed marked in vivo antitumor activity of TRAF6 inhibition. These findings support the theory that high expression of TRAF6 is a sign of more aggressive tumor behavior, and TRAF6 functions as an oncogene.
It has recently been documented that TRAF6 exhibits E3 ligase activity, and it might catalyze substrate ubiquitination. 25, 26 In an effort to identify the mechanism underlying TRAF6-induced malignant progression in cancer cells, we sought to explore whether TRAF6 triggers cancer cell proliferation by affecting the ubiquitination of certain substrates. As a serine/threonine protein kinase, AKT plays a key role in multiple cancer processes. 27, 28 Activated AKT could stimulate cancer cell proliferation and cell migration and influence cell cycle progression. Although the precise mechanism was unknown, it was reported that activation of AKT was often accompanied by TRF6 overexpression in cancers. 15, 29 Therefore, we speculated that TRAF6 might contribute to the malignant behavior of human cancers through affecting AKT ubiquitination. Our data showed that TRAF6 could efficiently catalyze the ubiquitination of AKT in cancer cells. As the intact RING domain of TRAF6 in conjunction with the E2 Ub-conjugating enzyme is necessary for its E3
ligase activity, an E3-ligase-deficient TRAF6 C70A mutant in which the highly critical Cys residue in its RING domain was mutated to Ala (TRAF6 C70A), was applied in our study to exclude a possible indirect effect of TRAF6 on AKT ubiquitination. In contrast to F I G U R E 7 Tumor necrosis factor receptor-associated factor 6 (TRAF6) contributes to tumor growth in vivo. A,B, Indicated treated cells were injected s.c. into immunocompromised mice (n = 6, each group). C-F, Growth curves of tumor volumes are shown for every group (left). Tumor weights were determined (right). G, Expression level of TRAF6 and the phosphorylation levels of AKT, IκB kinase (IKK), IκBα, p65, p38, JNK, and ERK were tested in tumor samples from each experimental group. Data represent mean ± SD, n = 6, *P < .05, **P < .01, Student's t test. mut, mutant; sh, shRNA TRAF6 wt, TRAF6 mut showed no influence on AKT ubiquitination, indicating that TRAF6 directly induced the ubiquitination of AKT.
The role of AKT signaling in cancer development has been well documented. 30 Aberrant activation of AKT signaling has been widely implicated in many cancers. 27, 28, 30 Although it is well known that AKT activity is regulated through phosphorylation, some other types of post-translational modifications, such as ubiquitination, SUMOylation, acetylation, and m6A mRNA methylation, have also been reported to promote AKT activity and function. 31, 32 Recently, it was reported that AKT ubiquitination is correlated with its phosphorylation level, suggesting that ubiquitination represents a novel post-translational modification that plays a key role in AKT activation. 33 Consistent with these reports, our data indicated that, in addition to ubiquitination, the ectopic expression of TRAF6 wt but not TRAF6 E3-ligase-deficient mut could also significantly facilitate AKT phosphorylation.
Moreover, the reconstitution of TRAF6 wt, but not TRAF6 mut, directly contributes to the proliferation, migration, and marked In summary, our findings indicate that TRAF6-mediated AKT ubiquitination and phosphorylation play important roles during the malignant progression of tumors. Our study also provides evidence that TRAF6 could be a potential therapeutic target in cancer.
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